We are all familiar with the phrase, "Save the Best for Last," and as we finish up our special GLP-1 Series, we have done exactly that.

This week we have the completion of an interview that our publisher, Steve Freed, did with Dr. David D'Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, about GLP-1 like compounds, beta cells and glucose toxicity.

We also have an upfront and personal interview that Steve had with Dr. Alan Moses, Chief Medical Officer at Novo Nordisk. During this conversation Dr. Moses shared some great info on GLP-1 Analogs, where the future might take us and current studies that Novo has on both Victoza and their new ultra long acting insulin degludec.

Steve, Andrew and I all send our greetings from AADE. Please look for our comprehensive coverage in upcoming issues.

With this special bonus edition of our highly successful GLP-1 special series, we provide you with an easy list so you can find all of our analyses in one place....

In this week's special bonus issue of our GLP-1 Special Series, we are very pleased to present an excellent and informative interview with Dr. Alan Moses, Global CMO, Novo Nordisk. Dr. Moses gives us his take on the latest in GLP-1 technologies as well as a peek at Novo's efforts in developing world-class therapies in the fight against diabetes....

This week, we present Part 2 of Diabetes In Control Publisher Steve Freed's interview with Dr. David D'Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, and the Albert Vontz chair in Diabetes Research. Dr. D'Alessio helps us understand some of the newest research on GLP-1's, how he uses these therapies in his own practice and what he's looking forward to in the pipeline....

This week we finish our analysis of our GLP-1 survey results with a look at prescribing reasons and habits, and how your colleagues decide on GLP-1 analog or DPP-4 inhibitor therapy. Most of the respondents favored Victoza but not as by as wide a margin as expected. Prescribers had a more even split as to which GLP1-Agonist they preferred than non-prescribers. The most common comment was that the once a day dosing of Victoza was a big advantage....

This week we examine more of your responses regarding GLP-1 therapy....

This week we have some results from our GLP-1 survey. Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are.